You searched for CNS - Page 6 of 15

News and Trends 17 Feb 2023

Report: China leads the way with phase 1 studies

Novotech, an Asia Pacific biotech CRO, has published a new global report on phase 1 trial activity including current metrics on fast growth regions and therapeutic areas. The data analysis found that Asia Pacific has been the fastest-growing region for phase 1 clinical trials in the last 10 years, reaching a share of 58% in […]

February 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 16 Feb 2023

Newron reports ‘striking’ schizophrenia study results

Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […]

February 16, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 6 Jan 2023

Beyond Biotech podcast 28: Mainz Biomed, Newron Pharmaceuticals

This week, we have two guests. We have conversations with Newron CEO, Stefan Weber, and Mainz Biomed CEO, Guido Bächler. Mainz Biomed year-end corporate review Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced its corporate summary for the fiscal year ended December 31, 2022. The company launched […]

January 6, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 3 Jan 2023

Newron announces interim results from treatment-resistant schizophrenia trial

Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […]

January 3, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 20 Dec 2022

Watch: IRLAB CEO Richard Godfrey

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […]

December 20, 2022 - 1 minutemin - By Jim Cornall

News and Trends 14 Dec 2022

STORM Therapeutics closes $30M Series B financing

STORM Therapeutics Ltd., which is working on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has successfully completed a $30 million Series B financing round. The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital (CIC) and new investors […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Dec 2022

PrecisionLife to work on R&D with Ono Pharmaceutical

PrecisionLife Limited has entered into a multi-target discovery and validation partnership with Ono Pharmaceutical Co., Ltd. The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono. PrecisionLife analyzes multi-modal datasets including genomic, clinical, and epidemiological data to […]

December 14, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 7 Dec 2022

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

Neuraxpharm Group, a European pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the establishment of Neuraxpharm Netherlands, increasing its presences from two to 20 countries in six years. The company says the expansion into the Dutch market allows it to continue on its pathway to become the number one […]

December 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 30 Nov 2022

TrialSpark acquires immunodermatology portfolio and creates Libertas Bio

TrialSpark has announced the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral phase 3-ready dual JAK/SYK inhibitor in development for chronic hand eczema (CHE), and ASN008, a phase 2-ready topical sodium […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Cell coding company bit.bio has made three additions to its product portfolio: ioGlutamatergic Neurons MAPT N279K and ioGlutamatergic Neurons MAPT P301S disease models, and early access to its ioGABAergic Neurons. This expands bit.bio’s central nervous system (CNS) portfolio to four disease models and three cell types. bit.bio’s cell products are reprogrammed from human induced pluripotent […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 10 Nov 2022

Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment

Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […]

November 10, 2022 - 3 minutesmins - By Liza Laws

Best in Biotech 10 Nov 2022

The five hottest biotech startup companies in Brazil

Brazil’s developing economy is supporting an emerging biotech startup scene. Catch a glimpse of the biotech companies causing a stir in Brazil. Over the decades, Brazil has grown into an agricultural powerhouse and has the biggest economy in South America. The nation is the world’s second-largest producer of biotech crops, with increasing land devoted to […]

November 10, 2022 - 4 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us